Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 87, Issue 6, Pages 871-877
Publisher
Springer Science and Business Media LLC
Online
2021-04-01
DOI
10.1007/s00280-021-04262-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration
- (2019) AnneMarthe Mjelstad et al. SUPPORTIVE CARE IN CANCER
- Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody
- (2019) Roger von Moos et al. CANCER TREATMENT REVIEWS
- Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
- (2019) Noam Yarom et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
- (2018) Noopur Raje et al. LANCET ONCOLOGY
- Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw
- (2018) Tomoko Higuchi et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study
- (2018) Aline Guillot et al. Clinical Genitourinary Cancer
- A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer
- (2017) Morten Schiodt et al. SUPPORTIVE CARE IN CANCER
- Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw
- (2016) Toshiyuki Yoneda et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events
- (2016) John Acquavella et al. Clinical Epidemiology
- Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
- (2015) Alison T. Stopeck et al. SUPPORTIVE CARE IN CANCER
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
- (2014) Aliya A Khan et al. JOURNAL OF BONE AND MINERAL RESEARCH
- American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
- (2014) Salvatore L. Ruggiero et al. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
- (2011) F. Saad et al. ANNALS OF ONCOLOGY
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?
- (2011) Tim Van den Wyngaert et al. SUPPORTIVE CARE IN CANCER
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started